Prolaris Helps to ID Prostate Cancer Patients Suited for Active Surveillance, Study Says

Prolaris Helps to ID Prostate Cancer Patients Suited for Active Surveillance, Study Says
Prolaris, a genetic test developed by Myriad Genetics to help predict the aggressiveness of prostate cancer, can accurately identify prostate cancer patients with low-risk disease who may safely opt for active surveillance, a study found. Among 547 men who choose active surveillance, only two experienced tumor progression during the study, corresponding to an event-free survival at five years of 98.5%. The study, “Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell-cycle risk score,” was published in the journal Future Medicine. Prostate cancer is the most common cancer among men, but a great number of cases will remain dormant and not progress to cause significant disability or risk of mortality. In these cases, active surveillance — an approach that consists of actively monitoring the cancer to detect progression before starting any treatment — is an accepted alternative to treatments that can carry significant side effects. The American Urological Association and the National Comprehensive Cancer Network (NCCN) guidelines consider active surveillance to be the standard approach for low-risk prostate cancer. Clinical exams to assess prostate cancer risk, however, can underestimate the number of patients who could benefit from active surveillance. Researchers estimate that only 40% to 50% of low-
Subscribe or to access all post and page content.

Tagged , , , .

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

Leave a Comment

Your email address will not be published. Required fields are marked *